Market Size and Annual Revenue Trajectory

Colorado opened the world's first legal recreational cannabis stores on January 1, 2014, building on a medical program that had already been operating for several years. Unlike markets where adult use launches into an immature medical channel, Colorado's medical program was an established $380M-a-year business the month adult use began — the two channels effectively coexisted from day one rather than one displacing the other over time.

Total revenue grew every year from 2014 through 2021, crossing $2B annually in 2020 and peaking at $2.24B in 2021. Colorado has now recorded four consecutive years of decline (2022–2025), with total revenue falling to $1.32B in 2025 — a 41% contraction from the 2021 peak. Revenue through the first half of 2026 ($633.5M across six months, running at roughly $105.6M/month) suggests the decline is decelerating but not reversing. Four consecutive years of decline is a long correction by any standard, and the first-half 2026 data (Table 1) shows no clear sign yet of the market finding a floor.

* 2026 data partial through June 2026. All figures in USD. 2014 figures sourced from the original DOR extract; 2015–2026 figures sourced from the state's public Tableau dashboard export, which revises 2021–2025 slightly upward (see Data Sources note) relative to the original extract.

Medical and Adult Use: A Diverging Trajectory

Colorado's channel dynamics differ structurally from newer legalization states. Medical was the dominant channel through 2014 — 55.6% of monthly revenue — but adult use overtook it within about a year. By 2025, medical represented just 9.8% of monthly revenue, down from 55.6% a decade earlier, and has fallen further to 8.6% through the first half of 2026. In some legalization states, medical revenue continues growing for a period after adult-use launch, particularly where the medical program is still young. Colorado's medical channel didn't have that runway: because medical and adult-use served an overlapping consumer base from day one, medical began losing share almost immediately once recreational stores opened.

Colorado's early growth also benefited from an outsized tourism effect that has faded as neighboring states opened their own markets. As one of only two states with legal recreational sales starting in 2014, Colorado drew heavily on out-of-state demand: a 2014 state analysis found that roughly 90% of recreational sales in Colorado's mountain resort towns came from out-of-state visitors, and dispensaries in border towns reported similarly high shares of out-of-state customers. That advantage narrowed as nearby states legalized their own recreational markets -- Arizona in 2021 and New Mexico in 2022 -- reducing the incentive for cross-border buyers to make the trip. Colorado's own legislative fiscal analysts have pointed to slowing cannabis-tourism demand from newly-legal neighboring states as a contributing factor in the state's declining tax revenue, alongside oversupply and a post-pandemic pullback in consumption. The timing lines up with the market's own trajectory: Colorado's revenue peaked in 2021, the same year Arizona's recreational market opened, with New Mexico following about a year later.

Washington offers the clearest peer comparison for Colorado's trajectory — both are original 2012-legalization states with no ownership-cap-driven consolidation ceiling, and both peaked in 2021 before entering sustained decline. Washington's total cannabis sales peaked at roughly $1.47B in 2021 and had fallen to approximately $1.14B by 2025 — a 22% decline, comparable in shape to Colorado's 41% drop from its own 2021 peak, though Colorado's contraction has been considerably steeper. Washington's decline is attributed to many of the same forces reshaping Colorado: chronic oversupply (licensed THC production nearly tripled between 2017 and 2023 while sales roughly doubled), and margin compression from the nation's highest cannabis excise tax (37%) combined with the federal Section 280E tax burden that applies in both states. One structural difference is worth noting: Washington's regulatory system never maintained Colorado's separate medical/adult-use sales tracking at the same granularity, so channel-level comparisons are less exact — the comparison here is best read at the total-market level.

Patient Enrollment: A Single, Volatile Measure

Colorado's registry data provides one primary metric — monthly active registered medical patients — rather than the dual cumulative-approval-vs-active-use split available in some other states. This is itself a data-availability note worth flagging: a cumulative lifetime-approval figure -- the kind some state medical registries track separately from active-patient counts -- was not present in the provided source file, so this section tracks active registrants only.

The early registry (2009–2012) was highly volatile: active patients grew from roughly 5,000 in early 2009 to a peak of 127,816 in July 2011, then fell sharply to under 81,000 by late 2012 — a swing that reflects the program's chaotic early years rather than a genuine shift in underlying demand, and predates any of the market and revenue data in this report. From 2014 (adult-use launch) onward, the pattern is more legible: active patients stood at 115,467 in December 2014 and have declined in most years since, reaching ~51,400 by June 2026 — a 55% decline from the 2014 level, and a 60% decline from the 2011 all-time peak.

Retail Expansion and the Licensing Structure

Store-count data covers May 2020 through June 2026, sourced from Emerald Intel. Colorado's active retail store count grew from 734 in May 2020 to a peak of 841 in mid-2022, before contracting to 757 by June 2026 — a modest net decline (-10%) that is far less pronounced than the store count's revenue backdrop would suggest, since Colorado's per-store economics have been compressing for longer.

Colorado's licensing structure has one notable feature: there is no statewide per-entity dispensary ownership cap — a 2018 reform (HB18-1011) repealed the prior limits on out-of-state investors and opened licensing to publicly traded entities, and vertical integration (single ownership across cultivation, manufacturing, and retail) is common and in some cases encouraged by the Marijuana Enforcement Division. Instead, license-count control in Colorado happens primarily at the local level: cities and counties opt in or out of allowing marijuana businesses altogether, and some jurisdictions — Colorado Springs among them — have frozen new license issuance entirely, capping location counts locally rather than through a statewide ownership formula. The result is a market with more dispensaries per capita than almost any other state, and consolidation pressure (see the Native Roots acquisition in Section 7) that plays out through open-market M&A rather than through a statewide ownership ceiling.

Store count source covers May 2020–Jun 2026 only. Revenue-per-store figures use adult-use revenue only; total active store count includes both medical and adult-use licensed dispensary locations; it does not include cultivation, manufacturing, or testing facility licenses.

Revenue per store fell from roughly $203K/month in May 2020 to approximately $131K/month by December 2025 — a decline of about 35%. That decline is comparatively moderate, largely because Colorado's per-store baseline was already much lower in 2020: with more stores per capita from the start (a legacy of the state's early and largely uncapped licensing approach), Colorado dispensaries never saw the extreme early-market revenue concentration that some newer-legalization markets experienced in their first one to two years.

Product Mix and Revenue Composition

Colorado's product-level data, sourced from the state's public dashboard, is available in two windows: an annual series covering 2018-2023 and a monthly series covering October 2025-June 2026, with a gap in between (2024 through September 2025) not present in either source. Both windows report category-share percentages rather than dollar figures directly; dollar values throughout this section were derived by applying each period's channel-specific (medical/adult-use) category shares to that period's actual revenue from Section 1. (The 2018-2023 dates were corrected from a corrupted year field in the source export and validated against CO_Product.xlsx's independent totals -- see Data Sources.)

The long-run trend shows a clear, gradual structural shift: flower's share fell from 50.1% of revenue in 2018 to 42.5% in 2023, while concentrate rose from 30.1% to 37.4% over the same span. That trend continued past the 2023 endpoint of the annual series and, by the time the monthly window picks back up in October 2025, concentrate (41.3%) has overtaken flower (38.6%) entirely -- a crossover this longer history shows was years in the making rather than a sudden 2025 shift. Edibles held a fairly narrow 12-15% range across both windows, and shake/trim stayed close to 5% throughout.

Annual totals derived from category shares x Section 1 revenue; shares capture ~98-99% of revenue per year, so totals run slightly below actual (see Data Sources).

Within the recent monthly window, category shares are stable -- concentrate holding 41-43%, flower 37-39%, edibles 14-15%, and shake/trim about 5% -- consistent with a market that finished its structural product-mix shift and has settled into a new equilibrium, rather than one still actively transitioning.

Conclusions: What the Colorado Data Tells Us

Developments to Watch

The following represent structural forces whose resolution will materially shape Colorado's cannabis market over the next one to three years. These are not predictions.